Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Small Molecule Libraries | 12 | 2025 | 135 | 3.720 |
Why?
|
| Drug Discovery | 7 | 2024 | 178 | 1.610 |
Why?
|
| Drug Design | 4 | 2021 | 165 | 1.590 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2025 | 194 | 1.410 |
Why?
|
| DNA | 8 | 2024 | 1444 | 1.400 |
Why?
|
| Piperazines | 2 | 2022 | 268 | 1.270 |
Why?
|
| Protease Inhibitors | 2 | 2022 | 95 | 0.860 |
Why?
|
| Proteolysis | 1 | 2025 | 189 | 0.840 |
Why?
|
| Molecular Structure | 9 | 2024 | 320 | 0.840 |
Why?
|
| Pyridines | 2 | 2021 | 258 | 0.810 |
Why?
|
| Diamines | 1 | 2022 | 8 | 0.750 |
Why?
|
| Alkenes | 2 | 2013 | 8 | 0.750 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2025 | 363 | 0.740 |
Why?
|
| Stereoisomerism | 7 | 2024 | 116 | 0.700 |
Why?
|
| Tudor Domain | 1 | 2021 | 4 | 0.690 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 39 | 0.680 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2020 | 8 | 0.680 |
Why?
|
| Fluorenes | 1 | 2020 | 7 | 0.670 |
Why?
|
| Molecular Probes | 1 | 2020 | 26 | 0.660 |
Why?
|
| Molecular Biology | 1 | 2020 | 68 | 0.640 |
Why?
|
| Peptides | 2 | 2020 | 835 | 0.630 |
Why?
|
| Staining and Labeling | 1 | 2020 | 170 | 0.630 |
Why?
|
| Contraceptive Agents, Male | 3 | 2024 | 37 | 0.550 |
Why?
|
| Antineoplastic Agents | 2 | 2025 | 1802 | 0.550 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2024 | 606 | 0.500 |
Why?
|
| Macrocyclic Compounds | 2 | 2011 | 13 | 0.430 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2024 | 50 | 0.410 |
Why?
|
| Structure-Activity Relationship | 4 | 2024 | 578 | 0.400 |
Why?
|
| Siloxanes | 1 | 2013 | 2 | 0.400 |
Why?
|
| Hydrocarbons, Halogenated | 1 | 2013 | 5 | 0.400 |
Why?
|
| Triazoles | 3 | 2021 | 144 | 0.380 |
Why?
|
| Molecular Conformation | 3 | 2021 | 98 | 0.360 |
Why?
|
| Luciferases | 3 | 2022 | 127 | 0.360 |
Why?
|
| Aza Compounds | 1 | 2011 | 13 | 0.360 |
Why?
|
| Silanes | 1 | 2011 | 1 | 0.350 |
Why?
|
| Ketones | 1 | 2011 | 27 | 0.350 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2011 | 5 | 0.350 |
Why?
|
| Nuclear Proteins | 3 | 2022 | 1227 | 0.330 |
Why?
|
| Azepines | 2 | 2021 | 62 | 0.330 |
Why?
|
| Biological Assay | 2 | 2022 | 108 | 0.320 |
Why?
|
| Ligands | 5 | 2022 | 485 | 0.310 |
Why?
|
| Catalysis | 5 | 2020 | 136 | 0.300 |
Why?
|
| Combinatorial Chemistry Techniques | 3 | 2021 | 15 | 0.290 |
Why?
|
| Signal Transduction | 6 | 2024 | 4645 | 0.290 |
Why?
|
| Transcription Factors | 3 | 2022 | 2430 | 0.250 |
Why?
|
| Databases, Factual | 1 | 2011 | 1220 | 0.240 |
Why?
|
| Esters | 2 | 2024 | 33 | 0.240 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2005 | 12 | 0.240 |
Why?
|
| Lithium | 1 | 2005 | 66 | 0.240 |
Why?
|
| Activin Receptors, Type I | 1 | 2024 | 34 | 0.220 |
Why?
|
| Pyridones | 1 | 2005 | 144 | 0.220 |
Why?
|
| Ubiquitination | 1 | 2025 | 171 | 0.210 |
Why?
|
| Neoplasms | 1 | 2019 | 2955 | 0.210 |
Why?
|
| Microsomes, Liver | 2 | 2023 | 96 | 0.210 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2025 | 237 | 0.210 |
Why?
|
| Protein Binding | 4 | 2022 | 1705 | 0.210 |
Why?
|
| Morpholines | 1 | 2024 | 68 | 0.210 |
Why?
|
| Enzyme Activation | 2 | 2022 | 586 | 0.210 |
Why?
|
| Contraception | 1 | 2024 | 62 | 0.200 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 281 | 0.200 |
Why?
|
| Neurogenesis | 2 | 2022 | 223 | 0.200 |
Why?
|
| Crystallography, X-Ray | 2 | 2021 | 365 | 0.200 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 3642 | 0.190 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2022 | 14 | 0.190 |
Why?
|
| Cosmic Radiation | 1 | 2022 | 13 | 0.190 |
Why?
|
| Acetic Acid | 1 | 2022 | 17 | 0.190 |
Why?
|
| Gold | 1 | 2022 | 55 | 0.190 |
Why?
|
| Oleic Acid | 1 | 2022 | 17 | 0.190 |
Why?
|
| Radiation Protection | 1 | 2022 | 47 | 0.190 |
Why?
|
| Radiation Exposure | 1 | 2022 | 41 | 0.180 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 134 | 0.180 |
Why?
|
| Astronauts | 1 | 2022 | 77 | 0.180 |
Why?
|
| Humans | 24 | 2025 | 130931 | 0.180 |
Why?
|
| Binding Sites | 2 | 2021 | 1200 | 0.170 |
Why?
|
| Radiation Injuries | 1 | 2022 | 138 | 0.170 |
Why?
|
| Solutions | 1 | 2020 | 53 | 0.170 |
Why?
|
| Histone Code | 1 | 2021 | 46 | 0.170 |
Why?
|
| Spliceosomes | 1 | 2021 | 49 | 0.170 |
Why?
|
| Oxygen | 1 | 2024 | 555 | 0.170 |
Why?
|
| Genetic Engineering | 1 | 2021 | 162 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 298 | 0.160 |
Why?
|
| Immunity | 1 | 2021 | 178 | 0.160 |
Why?
|
| Cyclization | 3 | 2020 | 17 | 0.160 |
Why?
|
| Hippocampus | 2 | 2022 | 794 | 0.160 |
Why?
|
| Oligopeptides | 1 | 2020 | 121 | 0.160 |
Why?
|
| Luminescent Measurements | 1 | 2019 | 56 | 0.160 |
Why?
|
| Animals | 13 | 2024 | 34278 | 0.160 |
Why?
|
| Models, Molecular | 2 | 2021 | 1084 | 0.160 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2022 | 327 | 0.150 |
Why?
|
| Space Flight | 1 | 2022 | 165 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2020 | 191 | 0.150 |
Why?
|
| Virus Replication | 1 | 2021 | 597 | 0.140 |
Why?
|
| Palladium | 2 | 2022 | 20 | 0.140 |
Why?
|
| Escherichia coli | 2 | 2021 | 981 | 0.140 |
Why?
|
| Drosophila melanogaster | 1 | 2023 | 841 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1625 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 565 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2019 | 197 | 0.130 |
Why?
|
| Histones | 1 | 2021 | 515 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 287 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2021 | 776 | 0.130 |
Why?
|
| Mice | 10 | 2024 | 18410 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 704 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2022 | 811 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2019 | 352 | 0.120 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2965 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 4 | 2022 | 1217 | 0.120 |
Why?
|
| Metabolomics | 3 | 2023 | 488 | 0.110 |
Why?
|
| Carcinoma, Ductal | 1 | 2013 | 9 | 0.100 |
Why?
|
| Substrate Specificity | 2 | 2011 | 285 | 0.100 |
Why?
|
| Chemistry, Organic | 1 | 2013 | 7 | 0.100 |
Why?
|
| Chromatography, Liquid | 2 | 2023 | 238 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3833 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 176 | 0.090 |
Why?
|
| Biological Products | 2 | 2010 | 144 | 0.090 |
Why?
|
| Carbamates | 1 | 2011 | 66 | 0.090 |
Why?
|
| Aldehydes | 1 | 2010 | 28 | 0.080 |
Why?
|
| Gene Library | 2 | 2023 | 213 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 286 | 0.080 |
Why?
|
| Testis | 2 | 2024 | 413 | 0.080 |
Why?
|
| Amino Acids | 2 | 2024 | 620 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 566 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2010 | 82 | 0.080 |
Why?
|
| Systems Biology | 1 | 2010 | 60 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2013 | 690 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 119 | 0.080 |
Why?
|
| Ruthenium | 1 | 2009 | 5 | 0.080 |
Why?
|
| Alkynes | 1 | 2009 | 28 | 0.080 |
Why?
|
| Disease | 1 | 2010 | 125 | 0.070 |
Why?
|
| Genes, Reporter | 2 | 2020 | 350 | 0.070 |
Why?
|
| Plasmids | 2 | 2020 | 455 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 1311 | 0.070 |
Why?
|
| Genetic Vectors | 2 | 2021 | 900 | 0.060 |
Why?
|
| High-Throughput Screening Assays | 2 | 2021 | 117 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 1975 | 0.060 |
Why?
|
| Activin Receptors, Type II | 1 | 2024 | 31 | 0.060 |
Why?
|
| Proteins | 1 | 2010 | 1025 | 0.060 |
Why?
|
| Blood-Testis Barrier | 1 | 2024 | 14 | 0.050 |
Why?
|
| Receptors, Eph Family | 1 | 2024 | 22 | 0.050 |
Why?
|
| Receptor, EphA2 | 1 | 2024 | 29 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2024 | 51 | 0.050 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2023 | 10 | 0.050 |
Why?
|
| Carbon | 1 | 2024 | 94 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2023 | 15 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2024 | 435 | 0.050 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2022 | 15 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2023 | 62 | 0.050 |
Why?
|
| Central Nervous System Agents | 1 | 2022 | 15 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2022 | 34 | 0.050 |
Why?
|
| Moon | 1 | 2022 | 13 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2022 | 49 | 0.050 |
Why?
|
| Luciferases, Firefly | 1 | 2022 | 11 | 0.050 |
Why?
|
| Propranolol | 1 | 2022 | 111 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 419 | 0.050 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2022 | 19 | 0.050 |
Why?
|
| Semen | 1 | 2022 | 85 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2022 | 99 | 0.050 |
Why?
|
| Glutathione | 1 | 2023 | 196 | 0.050 |
Why?
|
| Pyrroles | 1 | 2023 | 185 | 0.050 |
Why?
|
| Serotonin | 1 | 2022 | 212 | 0.040 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2021 | 15 | 0.040 |
Why?
|
| Protein Conformation, beta-Strand | 1 | 2021 | 14 | 0.040 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2021 | 15 | 0.040 |
Why?
|
| Protein Domains | 1 | 2022 | 249 | 0.040 |
Why?
|
| Endometriosis | 1 | 2024 | 184 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 58 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 135 | 0.040 |
Why?
|
| Cell Movement | 1 | 2024 | 874 | 0.040 |
Why?
|
| A549 Cells | 1 | 2020 | 49 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 147 | 0.040 |
Why?
|
| Buffers | 1 | 2020 | 29 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2021 | 228 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2021 | 252 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 100 | 0.040 |
Why?
|
| Introns | 1 | 2021 | 287 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2021 | 785 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2019 | 62 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2021 | 234 | 0.040 |
Why?
|
| Transfection | 1 | 2020 | 960 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 383 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 666 | 0.030 |
Why?
|
| Cognition | 1 | 2022 | 837 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 1500 | 0.030 |
Why?
|
| Male | 4 | 2024 | 64823 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2022 | 2459 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2022 | 3850 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1852 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 415 | 0.020 |
Why?
|
| Female | 3 | 2024 | 70755 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 152 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1490 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 211 | 0.020 |
Why?
|